InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,751.07
(
0.90%
)
US TECH 100
19,476.00
(
1.10%
)
Dow Jones
42,352.75
(
0.81%
)
Brent Oil
77.57
(
0.24%
)
Bitcoin
63,716.97
(
1.43%
)
Post# of 147314
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

marginplay

Send PM Follow Ignore
Followers 2
Posts 64
Boards Moderated 0
Alias Born 09/15/2017

marginplay

Re: None

Tuesday, 07/10/2018 3:46:02 AM

Tuesday, July 10, 2018 3:46:02 AM

Post# of 147314
DSM is the parent of Reverdia a joint venture from which BioAmber licenses a certain yeast formula. This is highly intriguing as it seems possible that DSM would buyout Bioamber and either house it as a separate subsidiary and therefor a market competitor to Reverdia (not sure this is the most efficient) or exert influence in the JV Reverdia (not sure of the controlling split) and put Bioamber under Reverdia...not sure anti-trust would allow this, Reverdia would have to make the decision independently of DSM I think...
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up